{'fraction_non_alphanumeric': 0.02890528905289053, 'fraction_numerical': 0.015990159901599015, 'mean_word_length': 5.8940677966101696, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Acute methamphetamine administration upregulates NGFI‐B mRNA expression in the striatum: Co‐localization with C‐FOS immunoreactivity

In this study, the effects of acute methamphetamine administration on expression of the nuclear transcription factor NGFI‐B mRNA and its co‐localization with c‐Fos immunoreactivity in the striatum were evaluated in animals receiving a single dose of methamphetamine (4 mg/kg) given at 2 or 6 h prior to perfusion. All animals received a daily saline injection for 6 days prior to methamphetamine treatment. We have found that, similar to c‐fos activation, NGFI‐B mRNA levels were significantly increased 2 h after methamphetamine treatment and returned to basal levels 6 h later. Induction of NGFI‐B mRNA levels by methamphetamine was highest in central striatum as compared to the dorsomedial distribution pattern observed in control animals. After acute methamphetamine treatment, the distribution pattern of NGFI‐B mRNA upregulation was very similar to that of methamphetamine induced c‐Fos immunoreactivity. However, co‐localization studies with c‐Fos immunoreactivity showed that not all NGFI‐B‐positive cells contained c‐Fos after methamphetamine treatment. Forty‐five percent of all NGFI‐B mRNA expressing neurons contained c‐Fos immunoreactivity in the dorsomedial striatum as compared to 60% in central and 35% in ventrolateral striatum. This study provides a detailed description of the differential spatial and temporal modulation of NGFI‐B and c‐Fos expression in the striatum by acute methamphetamine treatment over time. Synapse 44:158–165, 2002. Published 2002 Wiley‐Liss, Inc.